시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 지질 조정제 시장 보고서(2024년)
Lipid Regulators Global Market Report 2024
상품코드 : 1522246
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,060,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,590,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,120,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

지질 조정제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2028년에는 CAGR 7%로 95억 5,000만 달러로 성장합니다. 예측 기간 중의 성장은 심혈관 질환의 유병률 증가, 연령에 따른 죽상동맥경화증 발병률 증가, 비만율 증가, 대사증후군 유병률 증가, 맞춤형 의료에 대한 관심 증가에 기인하는 것으로 보입니다. 예측 기간 중 예상되는 주요 동향으로는 의약품 개발의 발전, 디지털 헬스 솔루션의 통합, 가치 기반 가격 책정 모델 도입, 일반의약품에 대한 수요 증가, 환자 중심의 약물 접근 방식 강화 등이 있습니다.

허혈성 심장질환의 발병률 증가는 당분간 지질 조절제 시장의 성장을 가속할 것으로 예상됩니다. 관상동맥질환(CAD)으로도 알려진 허혈성 심장질환(IHD)은 관상동맥이 좁아지거나 막혀서 심근으로 가는 혈류가 감소하는 질환입니다. 허혈성 심장질환의 유병률 증가 요인으로는 건강에 해로운 식습관, 흡연, 비만, 고혈압, 당뇨병 등이 있습니다. 지질 조절제는 LDL 콜레스테롤을 낮추고, HDL 콜레스테롤을 높이고, 동맥 플라크를 안정화시키고, 염증을 억제하고, 내피 기능을 강화하여 허혈성 심장 질환의 위험과 심각성을 감소시켜 허혈성 심장 질환 관리에 중요한 역할을 합니다. 예를 들어 2023년 12월 호주보건복지연구원(AIHW)이 발표한 자료에 따르면 2020-2021년 사이 허혈성 심장질환으로 인한 입원이 160,000건 발생했고, 2021년에만 17,300명이 사망한 것으로 나타났습니다. 그 결과, 허혈성 심장 질환의 유병률 증가는 지질 조절제 시장 확대의 주요 원인으로 작용하고 있습니다.

지질 조절제 시장의 신흥 국가 개척자들은 심장병 환자의 높은 저밀도 지단백(LDL) 콜레스테롤 수치에 대응하기 위해 첨단 경구용 지질 강하제 개발에 적극 나서고 있습니다. 이러한 경구용 약물은 고콜레스테롤을 유발하는 유전적 이상을 가진 환자나 심장병 진단을 받은 환자를 대상으로 합니다. 예를 들어 2022년 5월 인도의 전문 제네릭 제약사 Sun Pharmaceutical Industries Ltd는 심장병 환자의 고LDL 콜레스테롤 수치에 대한 획기적인 치료법을 제공하기 위해 고안된 경구용 약물인 벤페도산 브릴로를 인도에서 출시하였습니다. 벤페도산은 콜레스테롤 생성에 관여하는 효소인 ATP 구연산 리아제를 억제하고 간에서 콜레스테롤 합성을 조절하는 AMP 활성화 단백질 키나아제(AMPK)를 활성화시켜 이중 작용기전을 발휘합니다. 다른 콜레스테롤 저하제 대비 환자 편의성이 향상됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 합병과 인수

제35장 향후 전망과 잠재적 분석

제36장 부록

KSA
영문 목차

영문목차

Lipid regulators, also referred to as lipid-lowering drugs or hypolipidemic agents, are medications utilized to regulate blood lipid levels, specifically cholesterol and triglycerides. These drugs play a crucial role in minimizing the risk of cardiovascular disease, and they also possess anti-inflammatory properties that aid in stabilizing existing plaques and reducing the likelihood of plaque rupture and associated cardiovascular events.

The main types of lipid regulators include narcotic analgesics, angiotensin-converting enzyme (ACE) inhibitors, respiratory agents, diuretics, calcium antagonists, hormonal contraceptives, and others. Lipid regulators are medications designed to manage and control lipid levels in the body, including cholesterol and triglycerides. They are employed in treating various conditions such as hypercholesterolemia, hypertriglyceridemia, coronary artery disease, among others. These medications can be administered orally or via injection, and they find applications in pharmaceuticals, vaccines and drugs, scientific research, nutrition and supplements, food and beverages, and other sectors.

The lipid regulator market research report is one of a series of new reports from The Business Research Company that provides lipid regulator market statistics, including the lipid regulator industry global market size, regional shares, competitors with lipid regulator market share, detailed lipid regulator market segments, market trends, and opportunities, and any further data you may need to thrive in the lipid regulator industry. These lipid regulator market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lipid regulators market size has grown strongly in recent years. It will grow from $6.83 billion in 2023 to $7.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increased prevalence of lifestyle diseases, the growth in the aging population, increased awareness of lipid regulators, rising healthcare expenditure, and an increased focus on healthcare prevention.

The lipid regulators market size is expected to see strong growth in the next few years. It will grow to $9.55 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, the rising incidence of atherosclerosis with aging, increasing obesity rates, the growing prevalence of metabolic syndrome, and a growing focus on personalized medicine. Major trends expected during the forecast period include advancements in drug development, the integration of digital health solutions, adoption of value-based pricing models, increased demand for over-the-counter medications, and an emphasis on enhancing patient-centered medication approaches.

The increasing incidence of ischemic heart disease is anticipated to drive the expansion of the lipid regulator market in the foreseeable future. Ischemic heart disease (IHD), also known as coronary artery disease (CAD), involves the narrowing or blockage of coronary arteries, leading to reduced blood flow to the heart muscle. Factors contributing to the rising prevalence of ischemic heart disease include unhealthy diets, smoking, obesity, hypertension, and diabetes. Lipid regulators play a crucial role in managing ischemic heart disease by lowering LDL cholesterol, elevating HDL cholesterol, stabilizing arterial plaques, reducing inflammation, and enhancing endothelial function, thus mitigating the risk and severity of ischemic events. For instance, data from the Australian Institute of Health and Welfare (AIHW) in December 2023 revealed that between 2020 and 2021, there were 160,000 hospitalizations attributed to ischemic heart disease, resulting in 17,300 deaths in 2021 alone. Consequently, the growing prevalence of ischemic heart disease is a key driver behind the expansion of the lipid regulator market.

Leading companies in the lipid regulator market are actively developing advanced oral lipid-lowering medications to address high low-density lipoprotein (LDL) cholesterol levels in patients with heart conditions. These oral medications are targeted at individuals with inherited genetic abnormalities causing high cholesterol or those diagnosed with heart disease. For example, in May 2022, Sun Pharmaceutical Industries Limited, a specialty generic pharmaceutical company based in India, introduced Bempedoic Acid Brillo in India, an oral medication designed to provide innovative therapy for high LDL cholesterol levels in cardiac patients. Bempedoic acid exerts a dual mode of action by inhibiting ATP citrate lyase, an enzyme involved in cholesterol production, and activating AMP-activated protein kinase (AMPK), which regulates cholesterol synthesis in the liver. Its once-daily oral administration offers enhanced convenience for patients compared to certain other cholesterol-lowering medications.

In April 2023, Luye Pharma Group, a pharmaceutical company based in China, entered into a partnership with Duopharma Marketing Sdn Bhd with the objective of leveraging Duopharma Biotech's cardiovascular expertise and Luye Pharma's advanced technology to market and distribute a traditional Chinese medicine utilizing innovative fermentation techniques. This medicine harnesses unique red yeast rice to effectively manage cholesterol levels. Duopharma Marketing Sdn Bhd, a subsidiary of Duopharma Biotech Berhad (Duopharma Biotech), specializes in the manufacture of lipid regulators and cholesterol-lowering agents in Malaysia.

Major companies operating in the lipid regulators market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Limited, Dr. Reddy's Laboratories Ltd., Biocon Ltd., Alnylam Pharmaceuticals Inc., Amarin Corporation plc, Arrowhead Pharmaceuticals Inc., Kowa Pharmaceuticals America Inc. , Esperion Therapeutics Inc., Bentley Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Andrx Corporation

North America was the largest region in the lipid regulators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid regulators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lipid regulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The lipid regulators market consists of sales of ezetimibe, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lipid Regulators Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lipid regulators market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for lipid regulators ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lipid regulators market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Scope

Table of Contents

1. Executive Summary

2. Lipid Regulators Market Characteristics

3. Lipid Regulators Market Trends And Strategies

4. Lipid Regulators Market - Macro Economic Scenario

5. Global Lipid Regulators Market Size and Growth

6. Lipid Regulators Market Segmentation

7. Lipid Regulators Market Regional And Country Analysis

8. Asia-Pacific Lipid Regulators Market

9. China Lipid Regulators Market

10. India Lipid Regulators Market

11. Japan Lipid Regulators Market

12. Australia Lipid Regulators Market

13. Indonesia Lipid Regulators Market

14. South Korea Lipid Regulators Market

15. Western Europe Lipid Regulators Market

16. UK Lipid Regulators Market

17. Germany Lipid Regulators Market

18. France Lipid Regulators Market

19. Italy Lipid Regulators Market

20. Spain Lipid Regulators Market

21. Eastern Europe Lipid Regulators Market

22. Russia Lipid Regulators Market

23. North America Lipid Regulators Market

24. USA Lipid Regulators Market

25. Canada Lipid Regulators Market

26. South America Lipid Regulators Market

27. Brazil Lipid Regulators Market

28. Middle East Lipid Regulators Market

29. Africa Lipid Regulators Market

30. Lipid Regulators Market Competitive Landscape And Company Profiles

31. Lipid Regulators Market Other Major And Innovative Companies

32. Global Lipid Regulators Market Competitive Benchmarking

33. Global Lipid Regulators Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Lipid Regulators Market

35. Lipid Regulators Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기